{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:07:07Z","timestamp":1773115627938,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s13760-022-01926-z","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T05:02:38Z","timestamp":1655182958000},"page":"367-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cross-syndrome: myasthenia gravis and the demyelinating diseases of the central nervous system combination. Systematic literature review and case reports"],"prefix":"10.1007","volume":"123","author":[{"given":"Ekaterina","family":"Luzanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Nadtochiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-9931","authenticated-orcid":false,"given":"Elena","family":"Kryukova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Karpova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"issue":"3","key":"1926_CR1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3988\/jcn.2016.12.3.340","volume":"12","author":"SY Park","year":"2016","unstructured":"Park SY, Lee JY, Lim NG, Hong YH (2016) Incidence and prevalence of Myasthenia gravis in Korea: a populationbased study using the national health insurance claims database. J Clin Neurol 12(3):340\u2013344","journal-title":"J Clin Neurol"},{"issue":"3\u20134","key":"1926_CR2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000487886","volume":"50","author":"I Martinka","year":"2018","unstructured":"Martinka I, Fulova M, Spalekova M, Spalek P (2018) Epidemiology of Myasthenia gravis in Slovakia in the years 1977\u20132015. Neuroepidemiology 50(3\u20134):153\u2013159","journal-title":"Neuroepidemiology"},{"issue":"10","key":"1926_CR3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00115-019-00798-8","volume":"90","author":"W Mullges","year":"2019","unstructured":"Mullges W, Stoll G (2019) Myasthenia gravis. Nervenarzt 90(10):1055\u20131066","journal-title":"Nervenarzt"},{"issue":"10","key":"1926_CR4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"issue":"1","key":"1926_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.25207\/1608-6228-2018-25-1-195-198","volume":"25","author":"YAZNV Khatke","year":"2018","unstructured":"Khatke YAZNV, Ivanisova AV, Petropavlovskaya TA, Gerasimenko GA (2018) Epidemiological features of myastenia gravis. Kuban Sci Med Bull. 25(1):195\u2013198","journal-title":"Kuban Sci Med Bull."},{"issue":"3","key":"1926_CR6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.17650\/2222-8721-2018-8-3-12-18","volume":"8","author":"TMKVV Alekseeva","year":"2018","unstructured":"Alekseeva TMKVV, Stuchevskaya TR, Khalmurzina AN (2018) Epidemiologic studies of myasthenia gravis: literature review. Neuromuscular Dis 8(3):12\u201318","journal-title":"Neuromuscular Dis"},{"issue":"2","key":"1926_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189","journal-title":"Neurology"},{"issue":"11","key":"1926_CR8","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00415-019-09461-3","volume":"266","author":"K Kimura","year":"2019","unstructured":"Kimura K, Okada Y, Fujii C, Komatsu K, Takahashi R, Matsumoto S et al (2019) Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis. J Neurol 266(11):2743\u20132751","journal-title":"J Neurol"},{"issue":"20","key":"1926_CR9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","volume":"78","author":"MI Leite","year":"2012","unstructured":"Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D et al (2012) Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 78(20):1601\u20131607","journal-title":"Neurology"},{"issue":"5","key":"1926_CR10","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4103\/0028-3886.57817","volume":"57","author":"K Basiri","year":"2009","unstructured":"Basiri K, Etemadifar M, Maghzi AH, Zarghami N (2009) Frequency of myasthenia gravis in multiple sclerosis: report of five cases from Isfahan. Iran Neurol India 57(5):638\u2013640","journal-title":"Iran Neurol India"},{"issue":"6","key":"1926_CR11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1191\/1352458503ms964oa","volume":"9","author":"CM Isbister","year":"2003","unstructured":"Isbister CM, Mackenzie PJ, Anderson D, Wade NK, Oger J (2003) Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult Scler 9(6):550\u2013553","journal-title":"Mult Scler"},{"issue":"1","key":"1926_CR12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-510X(89)90005-1","volume":"89","author":"H Somer","year":"1989","unstructured":"Somer H, Muller K, Kinnunen E (1989) Myasthenia gravis associated with multiple sclerosis. Epidemiological survey and immunological findings. J Neurol Sci 89(1):37\u201348","journal-title":"J Neurol Sci"},{"issue":"2","key":"1926_CR13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.17712\/nsj.2018.2.20170343","volume":"23","author":"MH Alanazy","year":"2018","unstructured":"Alanazy MH, Alomar MA, Aljafen BN, Muayqil TA (2018) Multiple sclerosis and myasthenia gravis following severe weight loss. Neurosciences (Riyadh) 23(2):158\u2013161","journal-title":"Neurosciences (Riyadh)"},{"issue":"4","key":"1926_CR14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cytogfr.2014.07.013","volume":"25","author":"DW Luchtman","year":"2014","unstructured":"Luchtman DW, Ellwardt E, Larochelle C, Zipp F (2014) IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments. Cytokine Growth Factor Rev 25(4):403\u2013413","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"1926_CR15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","volume":"10","author":"JH Buckner","year":"2010","unstructured":"Buckner JH (2010) Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 10(12):849\u2013859","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1926_CR16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000362370","volume":"22","author":"V Mastorodemos","year":"2015","unstructured":"Mastorodemos V, Ioannou M, Verginis P (2015) Cell-based modulation of autoimmune responses in multiple sclerosis and experimental autoimmmune encephalomyelitis: therapeutic implications. NeuroImmunoModulation 22(3):181\u2013195","journal-title":"NeuroImmunoModulation"},{"key":"1926_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.05.001","volume":"52","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S (2014) Myasthenia Gravis: paradox versus paradigm in autoimmunity. J Autoimmun 52:1\u201328","journal-title":"J Autoimmun"},{"issue":"3","key":"1926_CR18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1073\/pnas.86.3.988","volume":"86","author":"JR Oksenberg","year":"1989","unstructured":"Oksenberg JR, Sherritt M, Begovich AB, Erlich HA, Bernard CC, Cavalli-Sforza LL et al (1989) T-cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis. Proc Natl Acad Sci USA 86(3):988\u2013992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1926_CR19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","volume":"14","author":"KM Danikowski","year":"2017","unstructured":"Danikowski KM, Jayaraman S, Prabhakar BS (2017) Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation 14(1):117","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1926_CR20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","volume":"74","author":"I Raphael","year":"2015","unstructured":"Raphael I, Nalawade S, Eagar TN, Forsthuber TG (2015) T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74(1):5\u201317","journal-title":"Cytokine"},{"key":"1926_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","volume":"52","author":"JS Yi","year":"2014","unstructured":"Yi JS, Guidon A, Sparks S, Osborne R, Juel VC, Massey JM et al (2014) Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. J Autoimmun 52:130\u2013138","journal-title":"J Autoimmun"},{"key":"1926_CR22","first-page":"740947","volume":"2014","author":"S Li","year":"2014","unstructured":"Li S, Jin T, Zhang HL, Yu H, Meng F, Concha Quezada H et al (2014) Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barre syndrome and downregulated by IVIg treatments. Mediators Inflamm 2014:740947","journal-title":"Mediators Inflamm"},{"key":"1926_CR23","first-page":"1","volume":"158","author":"J Link","year":"1994","unstructured":"Link J (1994) Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. Acta Neurol Scand Suppl 158:1\u201358","journal-title":"Acta Neurol Scand Suppl"},{"issue":"3","key":"1926_CR24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10753-012-9573-z","volume":"36","author":"J Lu","year":"2013","unstructured":"Lu J, Li J, Zhu TQ, Zhang L, Wang Y, Tian FF et al (2013) Modulation of B cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis. Inflammation 36(3):521\u2013528","journal-title":"Inflammation"},{"key":"1926_CR25","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","volume":"10","author":"C Kaegi","year":"2019","unstructured":"Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A et al (2019) Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol 10:1990","journal-title":"Front Immunol"},{"issue":"5","key":"1926_CR26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/joim.12310","volume":"277","author":"F Fang","year":"2015","unstructured":"Fang F, Sveinsson O, Thormar G, Granqvist M, Askling J, Lundberg IE et al (2015) The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med 277(5):594\u2013604","journal-title":"J Intern Med"},{"issue":"5","key":"1926_CR27","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/01.wnl.0000234142.41728.a0","volume":"67","author":"M Gotkine","year":"2006","unstructured":"Gotkine M, Fellig Y, Abramsky O (2006) Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 67(5):881\u2013883","journal-title":"Neurology"},{"issue":"5","key":"1926_CR28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000117285","volume":"36","author":"MR Tola","year":"1996","unstructured":"Tola MR, Casetta I, Granieri E, Caniatti LM, Monetti VC, Pascarella R (1996) Systemic lupus erythematosus related recurrent transverse myelitis in a patient with myasthenia gravis and multiple sclerosis. Eur Neurol 36(5):327\u2013328","journal-title":"Eur Neurol"},{"issue":"8","key":"1926_CR29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","volume":"18","author":"S Jarius","year":"2012","unstructured":"Jarius S, Paul F, Franciotta D, de Seze J, Munch C, Salvetti M et al (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 18(8):1135\u20131143","journal-title":"Mult Scler"},{"issue":"3","key":"1926_CR30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08916934.2014.883501","volume":"47","author":"A Iyer","year":"2014","unstructured":"Iyer A, Elsone L, Appleton R, Jacob A (2014) A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 47(3):154\u2013161","journal-title":"Autoimmunity"},{"issue":"12","key":"1926_CR31","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archneurol.2011.200","volume":"68","author":"A Vaknin-Dembinsky","year":"2011","unstructured":"Vaknin-Dembinsky A, Abramsky O, Petrou P, Ben-Hur T, Gotkine M, Brill L et al (2011) Myasthenia gravis- associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle? Arch Neurol 68(12):1557\u20131561","journal-title":"Arch Neurol"},{"key":"1926_CR32","doi-asserted-by":"crossref","first-page":"5389282","DOI":"10.1155\/2018\/5389282","volume":"2018","author":"T Mizrachi","year":"2018","unstructured":"Mizrachi T, Brill L, Rabie M, Nevo Y, Fellig Y, Zur M et al (2018) NMO-IgG and AQP4 peptide can induce aggravation of EAMG and immune-mediated muscle weakness. J Immunol Res 2018:5389282","journal-title":"J Immunol Res"},{"issue":"1\u20132","key":"1926_CR33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jneuroim.2013.08.016","volume":"264","author":"J Sylvester","year":"2013","unstructured":"Sylvester J, Purdie G, Slee M, Gray JX, Burnet S, Koblar S (2013) Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: a case report and literature review. J Neuroimmunol 264(1\u20132):130\u2013133","journal-title":"J Neuroimmunol"},{"issue":"9451","key":"1926_CR34","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106\u20132112","journal-title":"Lancet"},{"key":"1926_CR35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.msard.2019.06.027","volume":"34","author":"S Dehbashi","year":"2019","unstructured":"Dehbashi S, Hamouda D, Shanina E (2019) Co-occurrence of multiple sclerosis and myasthenia gravis: a case report and review of immunological theories. Mult Scler Relat Disord 34:135\u2013136","journal-title":"Mult Scler Relat Disord"},{"issue":"13","key":"1926_CR36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1212\/WNL.0000000000006251","volume":"91","author":"L Midaglia","year":"2018","unstructured":"Midaglia L, Gratacos M, Caronna E, Raguer N, Sastre-Garriga J, Montalban X et al (2018) Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. Neurology 91(13):622\u2013624","journal-title":"Neurology"},{"issue":"6","key":"1926_CR37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/135245859700300609","volume":"3","author":"S Dhib-Jalbut","year":"1997","unstructured":"Dhib-Jalbut S (1997) Mechanisms of interferon beta action in multiple sclerosis. Mult Scler 3(6):397\u2013401","journal-title":"Mult Scler"},{"issue":"3","key":"1926_CR38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/WNL.51.3.682","volume":"51","author":"VW Yong","year":"1998","unstructured":"Yong VW, Chabot S, Stuve O, Williams G (1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51(3):682\u2013689","journal-title":"Neurology"},{"issue":"7","key":"1926_CR39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/jnnp.2003.028233","volume":"75","author":"J Dionisiotis","year":"2004","unstructured":"Dionisiotis J, Zoukos Y, Thomaides T (2004) Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment. J Neurol Neurosurg Psychiatry 75(7):1079","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1926_CR40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.0b013e31827f07be","volume":"80","author":"BM Kluger","year":"2013","unstructured":"Kluger BM, Krupp LB, Enoka RM (2013) Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology 80(4):409\u2013416","journal-title":"Neurology"},{"issue":"5","key":"1926_CR41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pmrj.2010.04.012","volume":"2","author":"F Cantor","year":"2010","unstructured":"Cantor F (2010) Central and peripheral fatigue: exemplified by multiple sclerosis and myasthenia gravis. PM R 2(5):399\u2013405","journal-title":"PM R"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-022-01926-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-022-01926-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-022-01926-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T03:52:39Z","timestamp":1682567559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-022-01926-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1926"],"URL":"https:\/\/doi.org\/10.1007\/s13760-022-01926-z","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest and are fully responsible for the content and writing of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}